Wender Mieczysław
Neurol Neurochir Pol. 2003;37(4):777-82.
Early immunomodulatory treatment of multiple sclerosis has raised great hopes, especially among MS patients and their families. However, there are considerable differences of opinion among medical professionals, particularly as regards the economic aspect of the therapy (often undertaken before any definite diagnosis is made). The findings documenting early irreversible axonal lesions and brain atrophy in MS, as well as results of clinical studies suggest that early immunomodulatory treatment is the method of choice, even if critical arguments are taken into account.
多发性硬化症的早期免疫调节治疗带来了巨大希望，尤其是在多发性硬化症患者及其家属当中。然而，医学专业人员之间存在相当大的意见分歧，特别是在治疗的经济方面（通常在做出明确诊断之前就进行治疗）。记录多发性硬化症早期不可逆轴突损伤和脑萎缩的研究结果，以及临床研究结果表明，即使考虑到批判性观点，早期免疫调节治疗仍是首选方法。
